Intercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strain

Clin Microbiol Infect. 2011 Jan;17(1):52-6. doi: 10.1111/j.1469-0691.2010.03209.x.


In 2008, an increase in the prevalence of carbapenem-resistant Klebsiella pneumoniae was noted in a 286-bed tertiary case hospital in Colombia, where 84 patients (32 infected and 52 colonized) had positive cultures. The identified index patient came from Israel for a liver transplantation. High level carbapenem resistance was observed. Polymyxin B and tigecycline were the only two antibiotics that remained active. PCR-restriction fragment length polymorphism analysis and sequencing revealed blaKPC-3 in the major clone, which was indistinguishable from the K. pneumoniae carbapenemase-3-producing clone described previously in Israel. This exemplifies the threat posed by the global spread of K. pneumoniae carbapenemase-producing pathogens.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins / metabolism*
  • Colombia
  • Cross Infection / drug therapy
  • Cross Infection / microbiology*
  • Cross Infection / mortality
  • Cross Infection / transmission*
  • Humans
  • Israel
  • Klebsiella Infections / drug therapy
  • Klebsiella Infections / microbiology*
  • Klebsiella Infections / mortality
  • Klebsiella Infections / transmission*
  • Klebsiella pneumoniae / classification
  • Klebsiella pneumoniae / genetics
  • Klebsiella pneumoniae / isolation & purification
  • Molecular Typing
  • beta-Lactamases / metabolism*


  • Anti-Bacterial Agents
  • Bacterial Proteins
  • beta-Lactamases
  • beta-lactamase KPC-3, Klebsiella pneumoniae